Sobos article on retatrutide weight loss research also discusses retatrutide as a next-generation medication being studied for weight loss, not as an approved treatment that patients should obtain outside medical research or legitimate future prescribing pathways
Notably, GLP-1MK-801 also resulted in lower plasma triglycerides compared with MK-801 monotherapy
Because so many people are using these medications, its critical to monitor any ill effects on the eye or other parts of the body. The researchers have hypothesized that rapid changes in blood sugar levels might contribute to these complications, although the exact reason is still unclear
Careful and targeted patient selection are required, alongside robust education and novel technologies to monitor glucose and ketone levels to mitigate the risks and enhance the beneficial effects of SGLT2i and GLP-1 RA therapy
Common combinations include: Retatrutide + MOTS-c: Investigating mitochondrial efficiency alongside triple-incretin agonism
Retatrutide reduced HbA1c (a three-month average of blood sugar) by 1.8% at the 12mg dose in participants with type 2 diabetes